TITLE

Methodology of clinical trials in multiple sclerosis

AUTHOR(S)
Mitsikostas, D. D.
PUB. DATE
September 2006
SOURCE
Neurological Sciences;Sep2006 Supplement 5, Vol. 27, ps362
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The scope of the paper is to summarise key issues in methodology used in clinical trials on multiple sclerosis (MS) treatment and help clinicians to better understand articles reporting the results of these trials. Relapsing ratio and disability progression based on the Expanded Disability Status Scale are currently used as clinical efficacy primary outcomes, but more global measurements should be used in future such as the MS Functional Composite. For magnetic resonance imaging (MRI) outcomes, new MRI composites and indexes are already available (Z4 score, conventional MRI-derived end-points) that, together with new MRI techniques (magnetisation- transfer MRI and proton resonance spectroscopy), offer more precise neuroimaging assessments of the disease. These efficacy measurements should be presented in articles as number needed to treat, which assists the reader to calculate and compare the treatments’ power and safety.
ACCESSION #
22458750

 

Related Articles

  • Overview of London trial of intramuscular interferon-β1a in primary-progressive multiple sclerosis. Miller, David H.; Leary, Siobhan M.; Thompson, Alan J. // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10, p56 

    This short monograph describes the rationale, design and outcome of a pilot study of beta interferon in patients with primary progressive MS. A total of 50 patients were studied for 2 years using a randomized, double-blinded, placebo-controlled design. There was an emphasis on using MRI measures...

  • Glatiramer effective in delaying clinical MS.  // Formulary;Jun2008, Vol. 43 Issue 6, p220 

    The article reports on the findings of the study called PRECISE, a randomized trial of patients presented with a single clinical episode and a magnetic resonance imaging (MRI) scan suggestive of multiple sclerosis (MS). This study found that glatiramer provides a new option for delaying...

  • Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Boneschi, Filippo Martinelli; Rovaris, Marco; Johnson, Kenneth P; Miller, Aaron; Wolinsky, Jerry S; Ladkani, David; Shifroni, Galia; Comi, Giancarlo; Filippi, Massimo // Multiple Sclerosis (13524585);Aug2003, Vol. 9 Issue 4, p349 

    Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). Using raw data pooled from 540 patients, we performed a meta-analysis of these three trials,...

  • Magnetic resonance evidence of cortical onset of multiple sclerosis.  // Current Medical Literature: Multiple Sclerosis;2009, Vol. 1 Issue 3, p71 

    The article presents the report by Calabrese M. and Gallo P. describing the case histories of four patients presented with symptoms suggestive of multiple sclerosis (MS) but with normal conventional brain magnetic resonance imaging (MRI). A double inversion recovery (DIR) MIR sequencing to...

  • BIOMS REPORTS ON PHASE II DIRUCOTIDE FOR MULTIPLE SCLEROSIS.  // Worldwide Biotech;Mar2009, Vol. 21 Issue 3, p5 

    This article reports on the results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting multiple sclerosis (MS), released by BioMS Medical Corp. The results of the study showed that dirucotide did not meet its primary endpoint,...

  • The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Boneschi, Filippo Martinelli; Rovaris, Marco; Comi, Giancarlo; Filippi, Massimo // Multiple Sclerosis (13524585);Aug2004, Vol. 10 Issue 4, p341 

    Magnetic resonance imaging (MRI) is an important paraclinical tool for the diagnosis of multiple sclerosis (MS) and for monitoring its disease course. The efficacy of most of the available MS disease-modifying treatments has been tested in clinical trials where MRI-derived quantities served as...

  • Early treatment. Comi, G. // Neurological Sciences;May2006 Supplement 1, Vol. 27, ps8 

    Class I clinical trials demonstrated that immunomodulatory treatments (interferon-β and glatiramer acetate) reduce the disease activity and the accumulation of disability in relapsing–remitting multiple sclerosis (MS). Moreover, interferon-β-1b had similar positive effects also in...

  • Relationship between MRI lesion activity and response to IFN-β in relapsing-remitting multiple sclerosis patients. Río, J.; Rovira, À.; Tintoré, M.; Huerga, E.; Nos, C.; Tellez, N.; Tur, C.; Comabella, M.; Montalban, X. // Multiple Sclerosis (13524585);May2008, Vol. 14 Issue 4, p479 

    Objective Our objective in this study is to evaluate whether brain magnetic resonance imaging (MRI) performed at interferon-beta (IFN-β) onset and after 12 months allow us to identify relapsing-remitting multiple sclerosis (RRMS) patients with a disability increase in the first 2 years of...

  • Enhanced magnetic resonance imaging in multiple sclerosis. Filippi, M. // Multiple Sclerosis (13524585);Oct2000, Vol. 6 Issue 5, p320 

    Gadolinium-enhanced magnetic resonance imaging (MRI) is very sensitive in the detection of active lesions of multiple sclerosis (MS) and has become a valuable tool to monitor the evolution of the disease either natural or modified by treatment. In the past few years, several studies, on the one...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics